Search the Newsreel

Dynacons Systems Q1FY27 EBITDA up 26% to ₹40.19 crore; declares interim dividend

Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock

Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock on August 12, 2026, primarily to cover tax obligations related to Restricted Stock Unit vesting. Despite the sales, Mr. Koch also acquired new shares through vesting and was granted additional RSUs and stock …

Element Solutions declares $0.08 quarterly dividend By Investing.com

Element Solutions Inc (NYSE:ESI) has announced a quarterly cash dividend of $0.08 per share of common stock. The dividend is scheduled to be paid on September 15, 2026, to stockholders on record as of September 1, 2026. Element Solutions is a specialty chemicals technology …

Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT

Walleye Capital LLC has acquired a new position in PTC Therapeutics, Inc., purchasing 19,522 shares valued at approximately $1.59 million during the second quarter. Several other institutional investors also increased their holdings in the biopharmaceutical company, which has an average analyst rating of "Moderate …

LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research

Summit Global Investments Acquires Shares of 7,182 Vertex Pharmaceuticals Incorporated $VRTX

Summit Global Investments purchased 7,182 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in the second quarter, valued at approximately $3.57 million. Other hedge funds also adjusted their holdings, with institutional investors now owning 90.96% of the stock. Analysts currently have a "Moderate Buy" rating for VRTX …

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX

7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments

Summit Global Investments acquired 7,506 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) valued at $4.68 million during the second quarter. Regeneron reported strong quarterly results, beating analyst estimates with $14.29 EPS and $4.29 billion in revenue, representing a 16.7% year-over-year increase. Despite a "Moderate Buy" consensus …

Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST

Walleye Capital LLC has acquired a new stake of 282,568 shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST), valued at approximately $1.18 million. Institutional investors collectively hold 32.45% of the company's stock, while insider ownership stands at 6.81%. Despite a wider-than-expected quarterly loss, analysts maintain a …

Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock

An officer at Rhythm Pharmaceuticals (RYTM.US) recently sold a substantial amount of common stock, totaling US$8.9 million. This transaction indicates a significant insider sale for the company.

Walleye Capital LLC Makes New $1.42 Million Investment in Hillman Solutions Corp. $HLMN

Walleye Capital LLC has made a new investment of $1.42 million in Hillman Solutions Corp., acquiring 168,410 shares, which represents about 0.09% of the company's stock. Other institutional investors also adjusted their positions, with 98.11% of the stock owned by hedge funds and institutional …

Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC has acquired a new position in ANI Pharmaceuticals, purchasing 106,112 shares valued at approximately $8.8 million, indicating growing institutional interest as hedge funds and other investors collectively own 76.05% of the company. ANI Pharmaceuticals recently surpassed quarterly earnings expectations, reporting adjusted …

Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell"

Zacks Research downgraded Mineralys Therapeutics (NASDAQ:MLYS) to a "Strong Sell" rating, despite a mixed analyst sentiment with an average "Hold" rating and a $49.33 price target. The downgrade follows a significant earnings miss, with the company reporting a quarterly loss of $2.85 per share …

Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold

Zacks Research downgraded Monopar Therapeutics (NASDAQ:MNPR) from a "strong-buy" to a "hold" rating, despite the broader analyst consensus remaining a "moderate buy" with an average price target of $117.42. The company's shares opened at $113.04, trading near their 12-month high, and it recently reported …

Trifecta Capital Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Trifecta Capital Advisors LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 16,745 shares valued at approximately $8.318 million, making it their 27th largest holding. Other institutional investors like Capital Research Global Investors and State Street Corp also increased their stakes. This …

Oppenheimer Asset Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Oppenheimer Asset Management Inc. has acquired a new stake of 17,931 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $8.91 million during the second quarter. This new investment comes as other institutional investors have also adjusted their holdings in VRTX. Vertex Pharmaceuticals reported earnings …

Expleo Solutions Publishes Q1 FY2026 Unaudited Results in Newspapers

Walleye Capital LLC Purchases Shares of 102,163 Rapport Therapeutics, Inc. $RAPP

Walleye Capital LLC has acquired a new position in Rapport Therapeutics, purchasing 102,163 shares valued at $4.26 million, representing 0.21% of the company. Despite the stock opening near its 52-week high, Rapport Therapeutics reported a quarterly loss of $1.19 per share, missing estimates. Analysts …

86,249 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 86,249 shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, valued at approximately $3.12 million, representing a 0.31% stake in the company. This acquisition comes as Eton Pharmaceuticals reported strong quarterly results, exceeding revenue and EPS expectations, and …

Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Quantinno Capital Management LP significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 280.9% in Q1, acquiring an additional 24,878 shares to reach a total of 33,734 shares valued at $1.225 million. This comes as Crinetics Pharmaceuticals reported strong Q1 revenues of $25.12 …

128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 128,006 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the second quarter, a position valued at approximately $3.82 million. Despite this acquisition and a consensus "Buy" rating from analysts with an average price target of $66, the company reported a …

Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO

Walleye Capital LLC has invested $6.80 million in Allogene Therapeutics, acquiring 3.27 million shares, representing approximately 0.95% of the company. Other institutional investors have also adjusted their stakes, with a significant 83.63% of the stock owned by institutional investors and hedge funds. Allogene Therapeutics …

Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI

Walleye Capital LLC has acquired a new stake of 241,987 shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, valued at approximately $4.5 million. This investment contributes to the 95.76% institutional ownership of the company. Trevi Therapeutics maintains a "Buy" consensus rating from …

How (ADXN) Movements Inform Risk Allocation Models

This article analyzes Addex Therapeutics Ltd (NASDAQ: ADXN), highlighting a positive near-term sentiment but broader weak alignment. It presents an exceptional 60.0:1 risk-reward setup targeting a 20.6% gain against a 0.3% risk. The article outlines institutional trading strategies, including position trading, momentum breakout, and …

How Investors May Respond To ANI Pharmaceuticals (ANIP) Record Q2 Results And Reaffirmed 2026 Revenue Guidance

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen

Xchanging Solutions declares ₹2 per share final dividend for FY26

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

C4 Therapeutics (CCCC) gains 6.9% disclosed stake from Squadron Master Fund

Squadron Master Fund LP and related entities have disclosed a 6.9% beneficial ownership stake in C4 Therapeutics (CCCC), totaling 7,600,000 shares. This includes 7,200,000 common shares and 400,000 shares underlying currently exercisable long call options. The filing indicates shared voting and dispositive powers among …

Pioneer Power Solutions Q2 Net Loss Widens to $2.1 Million as Revenue Drops 40%

Pioneer Power Solutions (Nasdaq: PPSI) reported a widened net loss of $2.1 million in Q2 2026, compared to $1.3 million in the prior-year period, with revenue dropping 40% to $5.0 million. The company's financial performance reflects a challenging demand environment, marked by a significant …

Royal Bank of Canada Sells 88,061 Shares of Penguin Solutions, Inc. $PENG

Royal Bank of Canada reduced its stake in Penguin Solutions, Inc. by 31.4%, selling 88,061 shares but still holding 192,135 shares valued at $3.38 million. Despite this reduction, other major investors like Invesco and Paradigm Capital increased their positions. Penguin Solutions shares were up …

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

The Top 5 Analyst Questions From MACOM’s Q2 Earnings Call

The Top 5 Analyst Questions From MACOM's Q2 Earnings Call MACOM's second quarter was marked by significant revenue growth and strong market reaction, reflecting an acceleration in demand across its core end markets. Management attributed the quarter's performance to heightened demand for high-speed connectivity …

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …